Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CGON by emailGet an email when CGON pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CGON, unsubscribe in one click. Privacy
📣 What CGON Says Is Next
fourth quarter 2026 · “BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026”
Company press release, Aug 6, 2026 · SEC filing
fourth quarter 2026 · “The remaining CMC module is progressing as planned, and we are on track to finalize our submission in the fourth quarter 2026.”
Company press release, May 8, 2026 · SEC filing
fourth quarter 2026 · “Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026”
Company press release, May 8, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CGON picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CGON and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.